| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/02/2002 | EP1167526A1 IgE-dependent histamine-releasing factor(HRF)receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167369A1 Novel thiazolobenzimidazole derivatives |
| 01/02/2002 | EP1167357A1 Alpha-substituted carboxylic acid derivatives |
| 01/02/2002 | EP1167353A1 Morphan derivatives or salts thereof and medicinal compositions containing the same |
| 01/02/2002 | EP1167342A1 Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 01/02/2002 | EP1167341A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 01/02/2002 | EP1166793A1 Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165611A1 Retro-inverso prosaposin-derived peptides and use thereof |
| 01/02/2002 | EP1165610A1 Peptides useful in treating multiple sclerosis and a pharmaceutical composition comprising the same |
| 01/02/2002 | EP1165609A2 Human beta-secretase enzyme, inhibitors and their compositions and uses |
| 01/02/2002 | EP1165607A2 Protein (tp) that is involved in the development of the nervous system |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165604A2 Proteins related to neuronal regeneration and uses thereof |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165601A2 Prodrugs of thrombin inhibitors |
| 01/02/2002 | EP1165590A1 49 human secreted proteins |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165561A1 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents |
| 01/02/2002 | EP1165559A1 1,4-diazabicyclo 3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics |
| 01/02/2002 | EP1165557A1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165542A1 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
| 01/02/2002 | EP1165540A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 01/02/2002 | EP1165537A1 Hydroxymatairesinol in cancer prevention |
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165523A1 Neurotrophic substituted pyrimidines |
| 01/02/2002 | EP1165522A1 Neurotrophic thio substituted pyrimidines |
| 01/02/2002 | EP1165518A2 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors |
| 01/02/2002 | EP1165517A1 N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165510A1 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders |
| 01/02/2002 | EP1165502A1 Diaryl derivatives and their use as medicaments |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165487A1 Derivatives of venlafaxine and methods of preparing and using the same |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165118A2 Treatment of multiple sclerosis with a combination of interferon and growth hormone |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165101A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/02/2002 | EP1165100A2 Methods of treating schizophrenia |
| 01/02/2002 | EP1165090A2 A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 01/02/2002 | EP1165089A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies |
| 01/02/2002 | EP1165086A2 Bupropion metabolites and methods of their synthesis and use |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165083A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165064A2 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 01/02/2002 | EP1165054A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 01/02/2002 | EP1165044A2 High potency dihydroergotamine compositions |
| 01/02/2002 | EP1164996A1 Transdermal therapeutic system with nicotine and addition of monoterpene ketones |
| 01/02/2002 | EP1164991A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 01/02/2002 | EP1164874A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP1005372B1 Anti-cd40l immunotoxins for the treatment of diseases |
| 01/02/2002 | EP0941104A4 Peptide synthesis with sulfonyl protecting groups |
| 01/02/2002 | EP0873308B1 O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts |
| 01/02/2002 | EP0822829B1 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders |
| 01/02/2002 | EP0785938B1 Fused pyrrolocarbazoles |
| 01/02/2002 | EP0764157B1 Benzopyrans and their use as therapeutic agents |
| 01/02/2002 | EP0722457B1 Compounds modifying serotoninergic transmission, diagnostic and therapeutic applications |
| 01/02/2002 | CN1329674A A beta-peptide screeining methood |
| 01/02/2002 | CN1329668A Polyketide synthase enzymes and recombinant DNA constructs therefor |
| 01/02/2002 | CN1329620A Analogues of GLP-1 |
| 01/02/2002 | CN1329609A Tetrahydrobenza epine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| 01/02/2002 | CN1329605A Benzofuran derivatives their preparation and use |
| 01/02/2002 | CN1329601A New benzimidazolone-benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 01/02/2002 | CN1329599A 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 01/02/2002 | CN1329597A Pyridinium derivatives for treatment of diabetic and aging-related vascular complications |
| 01/02/2002 | CN1329594A Ureidopiperidine derivatives as selective human NK3 receptor antagonists |
| 01/02/2002 | CN1329590A Therapeutic product and its use |
| 01/02/2002 | CN1329589A N-aralkylaminotetralins as ligands for neuroptide YY5 receptor |
| 01/02/2002 | CN1329508A Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 01/02/2002 | CN1329493A Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 01/02/2002 | CN1329487A Dispersible compositions containing L-dopaethyl ester |
| 01/02/2002 | CN1329002A Intermediate product for preparing aralkyl and aryl alkylene heterocyclic lactam and imide |
| 01/02/2002 | CN1328848A Bimaxiancao capsule and its preparation method |
| 01/02/2002 | CN1328846A Chinese medicine preparation for curing headache |
| 01/02/2002 | CN1328835A Medicine preparation for curing abstinence and its application |
| 01/02/2002 | CN1328824A Compound for curing female sexual disorder |
| 01/02/2002 | CN1328823A Medicine for curing disease of deficiency in attention |
| 01/02/2002 | CN1328822A Medicine for curing Parkinson's disease |
| 01/02/2002 | CN1077104C Palladium catalyzed ring closure of triazolyl tryptamine |
| 01/02/2002 | CN1077103C Chiral methyl phenyl oxazolidinones |
| 01/01/2002 | US6335469 High purity (1R,2S,4R)-(-)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof |
| 01/01/2002 | US6335457 Complex containing biologically assimilable orthosilicic acid, which is under solid form, stable and concentrated, and a process for preparation of said complex |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335372 Administering 1,7,7-trimethyl-bicyclo(2.2.1)heptane derivatives, or their pharmaceutically acceptable acid addition salts |